WO2012158639A3 - Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection - Google Patents

Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection Download PDF

Info

Publication number
WO2012158639A3
WO2012158639A3 PCT/US2012/037831 US2012037831W WO2012158639A3 WO 2012158639 A3 WO2012158639 A3 WO 2012158639A3 US 2012037831 W US2012037831 W US 2012037831W WO 2012158639 A3 WO2012158639 A3 WO 2012158639A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treatment
prevention
fusion proteins
compositions
Prior art date
Application number
PCT/US2012/037831
Other languages
French (fr)
Other versions
WO2012158639A2 (en
Inventor
Kirill Kalnin
Harold Kleanthous
Yanhua Yan
Original Assignee
Sanofi Pasteur Biologics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics, Llc filed Critical Sanofi Pasteur Biologics, Llc
Publication of WO2012158639A2 publication Critical patent/WO2012158639A2/en
Publication of WO2012158639A3 publication Critical patent/WO2012158639A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to methods and compositions for production of fusion protein constructs useful for the treatment and/or prevent of infection, disease, and/or any related sequelae caused by or associated with transmission of one or more of the various types of human papillomavirus. The present invention further provides nucleic acid sequences that encode said compositions and fusion protein constructs as well as methods of therapeutic use and/or prophylactic use of said compositions and fusion protein constructs.
PCT/US2012/037831 2011-05-14 2012-05-14 Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection WO2012158639A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161519014P 2011-05-14 2011-05-14
US61/519,014 2011-05-14

Publications (2)

Publication Number Publication Date
WO2012158639A2 WO2012158639A2 (en) 2012-11-22
WO2012158639A3 true WO2012158639A3 (en) 2013-01-17

Family

ID=47177591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037831 WO2012158639A2 (en) 2011-05-14 2012-05-14 Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection

Country Status (1)

Country Link
WO (1) WO2012158639A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105177025B (en) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18 type recombinant human papilloma virus-like particle and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US20100303847A1 (en) * 2007-11-29 2010-12-02 Valerian Nakaar Compositions of toll-like receptor agonists and papillomavirus antigens and methods of use thereof
US20110171248A1 (en) * 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
US20100303847A1 (en) * 2007-11-29 2010-12-02 Valerian Nakaar Compositions of toll-like receptor agonists and papillomavirus antigens and methods of use thereof
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US20110171248A1 (en) * 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines

Also Published As

Publication number Publication date
WO2012158639A2 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2015085318A3 (en) Targeted adaptive vaccines
MX2021007268A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
MY158992A (en) Forms of rifaximin and uses thereof
MX2015005874A (en) Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
UA105290C2 (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX2012007710A (en) Alpha-amylases.
WO2012109373A3 (en) Treatment of osteoarthritis and pain
EA201370018A1 (en) COMPOSITIONS OF RIFAXIMINE AND THEIR APPLICATION
EA201390493A1 (en) HUMAN ANTIBODIES TO ONCOSTATINE M AND METHODS OF THEIR APPLICATION
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
EA201500371A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING DOUBLE ANGIPOETHIN-2 / Dll4 BINDING AGENTS AND ANTI-VEGF AGENTS
MX2013012233A (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines.
MX2014004953A (en) Tyrosine based linkers for the releasable connection of peptides.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12786493

Country of ref document: EP

Kind code of ref document: A2